{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:37:50Z","timestamp":1792553870706,"version":"4.5.0"},"reference-count":58,"publisher":"American Society of Hematology","issue":"20","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>CD19\u2013directed chimeric antigen receptor T-cell (CAR T) therapies, including axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), have transformed the treatment landscape for B-cell non-Hodgkin lymphoma, showcasing significant efficacy but also highlighting toxicity risks such as cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS). The US Food and Drug Administration has mandated patients remain close to the treatment center for 4\u00a0weeks as part of a Risk Evaluation and Mitigation Strategy to monitor and manage these toxicities, which, although cautious, may add to cost of care, be burdensome for patients and their families, and present challenges related to patient access and socioeconomic disparities. This retrospective study across 9 centers involving 475 patients infused with axi-cel, tisa-cel, and liso-cel from 2018 to 2023 aimed to assess CRS and ICANS onset and duration, as well as causes of nonrelapse mortality (NRM) in real-world CAR T recipients. Although differences were noted in the incidence and duration of CRS and ICANS between CAR T products, new-onset CRS and ICANS are exceedingly rare after 2\u00a0weeks after infusion (0% and 0.7% of patients, respectively). No new cases of CRS occurred after 2\u00a0weeks and a single case of new-onset ICANS occurred in the third week after infusion. NRM is driven by ICANS in the early follow-up period (1.1% until day 28) and then by infection through 3\u00a0months after infusion (1.2%). This study provides valuable insights into optimizing CAR T therapy monitoring, and our findings may provide a framework to reduce physical and financial constraints for patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012549","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T20:56:29Z","timestamp":1721768189000},"page":"5346-5354","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-4982","authenticated-orcid":false,"given":"Nausheen","family":"Ahmed","sequence":"first","affiliation":[{"name":"1Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Wesson","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forat","family":"Lutfi","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[{"name":"2Abramson Cancer Center and Center for Cell Therapy and Transplant, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-8610","authenticated-orcid":false,"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"4The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-7099","authenticated-orcid":false,"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[{"name":"6Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1614-8934","authenticated-orcid":false,"given":"Jamie","family":"Brower","sequence":"additional","affiliation":[{"name":"2Abramson Cancer Center and Center for Cell Therapy and Transplant, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy I.","family":"Chen","sequence":"additional","affiliation":[{"name":"6Knight Cancer Institute, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9641","authenticated-orcid":false,"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[{"name":"7Division of Hematology\/Oncology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8978","authenticated-orcid":false,"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"2Abramson Cancer Center and Center for Cell Therapy and Transplant, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"additional","affiliation":[{"name":"8David and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph P.","family":"McGuirk","sequence":"additional","affiliation":[{"name":"1Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0580","authenticated-orcid":false,"given":"Peter A.","family":"Riedell","sequence":"additional","affiliation":[{"name":"8David and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"issue":"19","key":"2024102212353569100_bib1","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2024102212353569100_bib2","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024102212353569100_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024102212353569100_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024102212353569100_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10254","key":"2024102212353569100_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"2024102212353569100_bib7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtct.2022.06.019","article-title":"Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"28","author":"Perales","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2024102212353569100_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10343","key":"2024102212353569100_bib9","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"26","key":"2024102212353569100_bib10","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024102212353569100_bib11","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2019001304","article-title":"Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Schuster","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2024102212353569100_bib12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2024102212353569100_bib13","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/bloodadvances.2019001305","article-title":"Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"key":"2024102212353569100_bib14","year":"2010"},{"issue":"4","key":"2024102212353569100_bib15","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"2024102212353569100_bib16","volume-title":"Breyanzi Risk Evaluation and Mitigation Strategy (REMS)","year":"2023"},{"key":"2024102212353569100_bib17","author":"Kymriah","year":"2022"},{"key":"2024102212353569100_bib18","year":"2017"},{"key":"2024102212353569100_bib19","year":"2024"},{"issue":"7","key":"2024102212353569100_bib20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2024102212353569100_bib21","doi-asserted-by":"crossref","first-page":"e2228877","DOI":"10.1001\/jamanetworkopen.2022.28877","article-title":"Geographic and racial disparities in access to chimeric antigen receptor\u2013T cells and bispecific antibodies trials for multiple myeloma","volume":"5","author":"Alqazaqi","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2024102212353569100_bib22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood.2022017866","article-title":"Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy","volume":"141","author":"Newman","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2024102212353569100_bib23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood.2022018552","article-title":"Access offsets poverty in quest for CAR T cells","volume":"141","author":"Rouce","year":"2023","journal-title":"Blood"},{"key":"2024102212353569100_bib24","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0","year":"2017"},{"key":"2024102212353569100_bib25","author":"Neelapu","year":"30  2022"},{"key":"2024102212353569100_bib26","unstructured":"Neelapu\n              TO\n            \n          . Many Challenges, Opportunities for CAR T-Cell Therapies in Lymphoma. Targeted Oncology; 2022. Accessed 12 April 2024. https:\/\/www.targetedonc.com\/view\/many-challenges-opportunities-for-car-t-cell-therapies-in-lymphoma."},{"issue":"12","key":"2024102212353569100_bib27","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"7","key":"2024102212353569100_bib28","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtct.2021.01.014","article-title":"Chimeric antigen receptor T cell therapy: a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration","volume":"27","author":"Alexander","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"13 suppl","key":"2024102212353569100_bib29","first-page":"S253","article-title":"Improving outcomes and mitigating costs associated with CAR T-cell therapy","volume":"27","author":"Borgert","year":"2021","journal-title":"Am J Manag Care"},{"issue":"7","key":"2024102212353569100_bib30","doi-asserted-by":"crossref","first-page":"449.e1","DOI":"10.1016\/j.jtct.2023.04.019","article-title":"Patient characteristics and outcomes of outpatient tisagenlecleucel recipients for B cell non-Hodgkin lymphoma","volume":"29","author":"Ahmed","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2024102212353569100_bib31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","article-title":"Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"29","author":"Hoffmann","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2024102212353569100_bib32","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2217\/imt-2022-0037","article-title":"Barriers and solutions to improve access for chimeric antigen receptor therapies","volume":"14","author":"Kamal-Bahl","year":"2022","journal-title":"Immunotherapy"},{"issue":"suppl 1","key":"2024102212353569100_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-136201","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"136","author":"Iacoboni","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2024102212353569100_bib34","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"2024102212353569100_bib35","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood-2023-184862","article-title":"Lisocabtagene maraleucel in relapsed\/refractory large B-cell lymphoma: real world analysis from the Cell Therapy Consortium","volume":"142","author":"Riedell","year":"2023","journal-title":"Blood"},{"issue":"6","key":"2024102212353569100_bib36","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtct.2023.03.021","article-title":"Bridging the gap: early transition and hybrid models of care to improve access to chimeric antigen receptor T cell therapy","volume":"29","author":"Ahmed","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2024102212353569100_bib37","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"issue":"10297","key":"2024102212353569100_bib38","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2024102212353569100_bib39","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024102212353569100_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2024102212353569100_bib41","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2024102212353569100_bib42","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024102212353569100_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2024102212353569100_bib44","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1182\/blood-2019-131170","article-title":"Infectious complications associated with CAR T-cell therapy","volume":"134","author":"Mikkilineni","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2024102212353569100_bib45","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"24","key":"2024102212353569100_bib46","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2024102212353569100_bib47","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy-a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers"},{"issue":"15","key":"2024102212353569100_bib48","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2024102212353569100_bib49","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"issue":"20","key":"2024102212353569100_bib50","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2024102212353569100_bib51","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"2024102212353569100_bib52","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cmi.2023.05.011","article-title":"Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: a systematic scoping review and narrative synthesis","volume":"29","author":"Reynolds","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"2024102212353569100_bib53","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"16 suppl","key":"2024102212353569100_bib54","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2023.41.16_suppl.7507","article-title":"Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R\/R) mantle cell lymphoma (MCL): a CIBMTR subgroup analysis by prior treatment","volume":"41","author":"Kambhampati","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024102212353569100_bib55","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"15 suppl","key":"2024102212353569100_bib56","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1200\/JCO.2020.38.15_suppl.8057","article-title":"Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel)","volume":"38","author":"Ahmed","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024102212353569100_bib57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"35","key":"2024102212353569100_bib58","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/20\/5346\/2247407\/blooda_adv-2023-012549-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/20\/5346\/2247407\/blooda_adv-2023-012549-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T12:36:00Z","timestamp":1729600560000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/20\/5346\/517124\/Optimizing-the-post-CAR-T-monitoring-period-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":58,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,10,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012549","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]}}}